^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Monjuvi (tafasitamab-cxix)

    i
    Other names: MOR-208, MOR 208, MOR00208, INCMOR0208, ICP-B04, ICPB04, ICP B04, INCMOR-0208, INCMOR 0208, MOR 00208, XENP5574, XENP 5574, XmAb 5574, XmAb-5574, INCA000585, INCA-000585, MOR208, MOR-00208, XmAb5574, XENP-5574
    Company:
    Incyte, InnoCare, Knight Therap, Specialised Therap, Xencor
    Drug class:
    CD19 inhibitor
    Related drugs:
    14d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Recruiting, David Bond, MD | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)
    22d
    Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=27, Suspended, City of Hope Medical Center | Active, not recruiting --> Suspended
    Trial suspension • First-in-human
    |
    Monjuvi (tafasitamab-cxix)
    24d
    Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    Monjuvi (tafasitamab-cxix)
    28d
    Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P1, N=27, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    clonoSEQ
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Monjuvi (tafasitamab-cxix)
    1m
    Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Apr 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • Monjuvi (tafasitamab-cxix)
    1m
    Exploring CD19-targeted Immunotherapy Strategies for Human B-cell Lymphoma. (PubMed, Arch Razi Inst)
    There are several FDA-approved anti-CD19 CAR-T cells, including Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel, as well as anti-CD19 monoclonal antibodies (mABs), such as loncastuximab tesirine and tafasitamab...Blinatumomab, the inaugural FDA-approved antibody to be produced using BiTE technology, has demonstrated notable benefits in clinical trials investigating its use in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)...Furthermore, we engaged in a discourse on the various treatment options concerning CD19 targeting, accompanied by an exposition of the pertinent clinical studies. In this regard, the efficacy, safety, and limitations of each option were thoroughly delineated.
    Review • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD79B (CD79b Molecule) • CD52 (CD52 Molecule)
    |
    Blincyto (blinatumomab) • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • Zynlonta (loncastuximab tesirine-lpyl) • Monjuvi (tafasitamab-cxix)
    2ms
    The emerging role of tafasitamab in follicular lymphoma. (PubMed, Leuk Lymphoma)
    Tafasitamab, a humanized anti-CD19 monoclonal antibody, is currently approved, in combination with lenalidomide, for relapsed refractory (R/R) diffuse large B-cell lymphoma (DLBCL), and together with lenalidomide and rituximab for R/R FL. This chemotherapy-free regiment is added with its favorable safety profile to more complex therapies such as CAR T-cell therapy or bispecific antibodies. Further studies are needed to clarify tafasitamab's durability of benefit, optimal sequencing, and integration within the evolving FL treatment landscape.
    Review • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • lenalidomide • Monjuvi (tafasitamab-cxix)
    2ms
    Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Karyopharm Therapeutics Inc | N=350 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • lenalidomide • oxaliplatin • Xpovio (selinexor) • bendamustine • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)
    3ms
    A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL (clinicaltrials.gov)
    P2, N=36, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Aug 2025 --> Aug 2027
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    lenalidomide • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    3ms
    frontMIND: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (clinicaltrials.gov)
    P3, N=899, Active, not recruiting, Incyte Corporation | Trial completion date: May 2026 --> Nov 2027 | Trial primary completion date: Jun 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Monjuvi (tafasitamab-cxix)
    3ms
    Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=6, Terminated, Pfizer | Phase classification: P2 --> P1/2
    Phase classification
    |
    lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
    4ms
    ECLAT: A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=27, Recruiting, Memorial Sloan Kettering Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)